Direct me to authoritative sources (NCCN, ASCO, NCI) where I can read the actual guidelines? THANKS

May 19, 2026Navis AI

Ask Navis about your situation

This answer is general. Get one about your specific case — no signup, answered right here.

For informational purposes only

This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.

DIRECT LINKS TO AUTHORITATIVE GUIDELINES FOR YOUR PROSTATE CANCER SURVEILLANCE

Great question. Here are the official sources where you can read the actual guidelines I should have cited more specifically:


1. NCCN (National Comprehensive Cancer Network) - PRIMARY SOURCE

Website: https://www.nccn.org/professionals/physician_gls/default.aspx

What to Look For:

  • Search: "Prostate Cancer"
  • Look for: "NCCN Clinical Practice Guidelines in Oncology - Prostate Cancer"
  • Current version: 2024-2025 (updated regularly)

What You'll Find: ✓ Post-operative surveillance recommendations ✓ PSA monitoring schedules ✓ Risk stratification (low, intermediate, high-risk) ✓ Recurrence detection protocols ✓ Treatment options if recurrence occurs

Note: NCCN guidelines are the gold standard that most U.S. oncologists follow. Your doctor likely uses these.

Access Level:

  • Free registration required (no cost)
  • Full guidelines available to patients
  • Can download PDF versions

2. ASCO (American Society of Clinical Oncology) - CLINICAL RECOMMENDATIONS

Website: https://www.asco.org/research-guidelines/guidelines

What to Look For:

  • Search: "Prostate Cancer Surveillance"
  • Look for: "Guideline for Management of Prostate Cancer"
  • Also search: "PSA Testing" recommendations

What You'll Find: ✓ Evidence-based surveillance intervals ✓ PSA testing recommendations post-treatment ✓ When imaging is indicated ✓ Risk-based follow-up strategies ✓ Treatment of recurrent disease

Note: ASCO provides detailed clinical guidance used by oncologists nationwide.

Access Level:

  • Free access to guideline summaries
  • Full articles may require subscription (check your hospital library)
  • Patient-friendly summaries available

3. NCI (National Cancer Institute) - PATIENT-FRIENDLY INFORMATION

Website: https://www.cancer.gov/types/prostate

What to Look For:

  • "Prostate Cancer Treatment (PDQ)"
  • "Prostate Cancer Screening (PDQ)"
  • "Follow-up Care After Treatment"

What You'll Find: ✓ Plain-language explanations of surveillance ✓ What PSA testing means ✓ Signs of recurrence to watch for ✓ Treatment options explained simply ✓ Links to clinical trials

Note: NCI is the U.S. government's cancer information resource. Very reliable and patient-focused.

Access Level:

  • Completely free
  • Written for patients (not just doctors)
  • Regularly updated with latest evidence

4. ASTRO (American Society for Radiation Oncology) - IF CONSIDERING RADIATION

Website: https://www.astro.org/Clinical-Practice/Guidelines-Publications

What to Look For:

  • "Prostate Cancer Guidelines"
  • Relevant if you're considering salvage radiation therapy

What You'll Find: ✓ Radiation therapy recommendations ✓ Timing of radiation after surgery ✓ Combination approaches

Access Level:

  • Free summaries available
  • Full guidelines may require registration

5. AMERICAN CANCER SOCIETY - PATIENT RESOURCES

Website: https://www.cancer.org/cancer/types/prostate-cancer.html

What to Look For:

  • "After Treatment"
  • "Follow-up Care"
  • "Understanding Your Pathology Report"

What You'll Find: ✓ What to expect during surveillance ✓ PSA testing explained ✓ Signs of recurrence ✓ Emotional/quality of life support

Access Level:

  • Completely free
  • Very patient-friendly
  • Excellent for understanding basics

6. CANCER COMMONS - EVIDENCE SUMMARIES

Website: https://www.cancercommons.org/

What to Look For:

  • "Prostate Cancer"
  • Evidence summaries for treatment options

What You'll Find: ✓ Curated evidence summaries ✓ Treatment comparisons ✓ Clinical trial information

Access Level:

  • Free access
  • Peer-reviewed summaries

WHAT TO LOOK FOR IN THESE GUIDELINES:

When you visit these sites, search specifically for:

For Your Post-RARP Surveillance:

  • ✓ "Biochemical recurrence" definition
  • ✓ "PSA doubling time"
  • ✓ "Surveillance intervals" post-prostatectomy
  • ✓ "Risk stratification" (low, intermediate, high-risk)
  • ✓ "Salvage therapy" options if PSA rises

For Understanding Your Results:

  • ✓ "Pathology reporting" for prostate cancer
  • ✓ "Gleason score" interpretation
  • ✓ "Surgical margins" significance
  • ✓ "Extraprostatic extension" meaning

For Your Specific Situation:

  • ✓ Your Gleason score risk category
  • ✓ Your pathological stage (pT2, pT3a, pT3b)
  • ✓ Margin status (positive vs. negative)
  • ✓ Recommended surveillance schedule for YOUR risk group

HOW TO USE THESE SOURCES:

Step 1: Start with NCI or American Cancer Society

  • Read patient-friendly explanations first
  • Understand the basic concepts

Step 2: Move to NCCN or ASCO Guidelines

  • Read the surveillance recommendations
  • Look for your specific risk category
  • Note the recommended PSA testing intervals

Step 3: Bring Questions to Your Oncologist

  • "I read that NCCN recommends X... is that what you're recommending for me?"
  • "Can you explain how these guidelines apply to my specific case?"
  • "Are there any reasons you're deviating from these recommendations?"

Step 4: Get Your Personalized Plan in Writing

  • Ask your doctor to document YOUR specific surveillance schedule
  • Request they reference which guidelines they're following
  • Keep this for your records

IMPORTANT CAVEAT:

These guidelines are general recommendations. Your oncologist may modify them based on:

  • Your specific pathology findings
  • Your individual risk factors
  • Your preferences and values
  • Your overall health status
  • Institutional protocols

Your doctor should explain:

  • Which guidelines they're following
  • How your case fits into those guidelines
  • Any modifications they're making and why

SPECIFIC QUESTIONS TO ASK YOUR ONCOLOGIST:

When you meet with your doctor, bring these questions:

  1. "Which guidelines are you using for my surveillance plan?"

    • (NCCN? ASCO? Institutional protocol?)
  2. "Based on my pathology, what risk category am I in?"

    • (Low, intermediate, or high-risk?)
  3. "What PSA surveillance schedule do you recommend?"

    • (Every 6 months? Annually? Other?)
  4. "What PSA level would trigger further evaluation?"

    • (What's your threshold for concern?)
  5. "Can you provide me with a written surveillance plan?"

    • (So you have it documented)
  6. "Are you following NCCN/ASCO guidelines, or do you have reasons to modify them?"

    • (Helps you understand their reasoning)

MY COMMITMENT TO YOU:

Going forward, when I help you understand your surveillance plan, I will:

Cite specific guidelines - "According to NCCN Guidelines 2024-2025..." ✅ Direct you to sources - "You can read this at nccn.org..." ✅ Acknowledge limitations - "I don't have access to the specific version..." ✅ Recommend your doctor - "Your oncologist will determine YOUR plan..." ✅ Help you engage - "Here are questions to ask your care team..."


NEXT STEPS:

  1. Visit these websites and read about prostate cancer surveillance
  2. Bring your questions to your next oncology appointment
  3. Ask for your written surveillance plan referencing the guidelines
  4. Come back to me if you need help understanding what you read

**You're doing exactly what you should be doing - becoming an informed patient who understands

Ask Navis about your case

That answer is general. Ask about your specific situation — no signup, answered right here.

Facing this with someone you love?

Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.

Start a care circle →

Related Questions

Just finished the perspective therapeutics VMT-a-NET phase 1b dosing trial These are the results of my latest PET...

TL;DR: Your latest PET scan shows your cancer is stable—the tumors in your liver are about the same size as before, no new tumors appeared, and the tr

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

We are in the UK royal marsden. It is kind of hopeless or how to say? Is there any immunetherapy worth to pursue or...

TL;DR: Diffuse midline gliomas DMGs with H3K27M are very challenging, but immunotherapy and targeted approaches are actively being researched—the Roya

It is my daughter she completed 6 weeks of radio and tmz now she is on 3rd cycle of tmz 200mg. We are doing low meth...

TL;DR: Your daughter's treatment plan radiation + TMZ chemotherapy is standard for diffuse midline glioma, and her biomarkers MGMT methylated, EGFR A2